MYELOPROLIFERATIVE DISORDER
Clinical trials for MYELOPROLIFERATIVE DISORDER explained in plain language.
Never miss a new study
Get alerted when new MYELOPROLIFERATIVE DISORDER trials appear
Sign up with your email to follow new studies for MYELOPROLIFERATIVE DISORDER, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New drug combo may make cord blood transplants safer for blood cancer patients
Disease control CompletedThis study tested whether adding the drug tocilizumab to standard care could reduce the risk of graft-versus-host disease (GVHD) after a cord blood transplant in adults with blood cancers. GVHD is a serious complication where donor cells attack the patient's body. Tocilizumab blo…
Matched conditions: MYELOPROLIFERATIVE DISORDER
Phase: PHASE2 • Sponsor: Memorial Sloan Kettering Cancer Center • Aim: Disease control
Last updated Jun 27, 2026 12:38 UTC
-
New Two-Step transplant shows promise for blood cancer patients
Disease control CompletedThis study tested a two-step stem cell transplant for people with blood cancers like leukemia and lymphoma. First, patients received low-dose chemotherapy and radiation to prepare their bodies. Then, they got donor stem cells followed by drugs to prevent the donor cells from atta…
Matched conditions: MYELOPROLIFERATIVE DISORDER
Phase: PHASE2 • Sponsor: Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University • Aim: Disease control
Last updated Jun 27, 2026 12:08 UTC
-
New Two-Step transplant shows promise for tough blood cancers
Disease control CompletedThis phase 2 trial tested a two-step stem cell transplant approach for 47 patients with high-risk blood cancers like leukemia and lymphoma. The method uses the drug cyclophosphamide to lower the chance of graft-versus-host disease (GVHD), a common complication. The goal was to se…
Matched conditions: MYELOPROLIFERATIVE DISORDER
Phase: PHASE2 • Sponsor: Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University • Aim: Disease control
Last updated Jun 27, 2026 11:03 UTC
-
Itch relief showdown: which drug stops water-induced agony?
Symptom relief CompletedThis study tested two oral medications, aprepitant and hydroxyzine, to see which better reduces severe itching triggered by water contact in people with myeloproliferative neoplasms (a type of blood cancer). 63 participants who had persistent itching rated 5 or higher on a 10-poi…
Matched conditions: MYELOPROLIFERATIVE DISORDER
Phase: PHASE3 • Sponsor: University Hospital, Brest • Aim: Symptom relief
Last updated Jun 27, 2026 08:01 UTC